Removed from CMC List: Can WuXi AppTec Finally Breathe a Sigh of Relief?

Deep News11-12

In terms of the frequency of disclosure announcements, "CXO leader" WuXi AppTec Co.,Ltd. (603259.SH) is not particularly high-profile, but on November 10 it delivered a piece of "great news for all": the company was removed by the U.S. Department of Defense from the CMC restriction list under Section 1260H!

According to a WuXi AppTec announcement, on November 9, the U.S. Department of Defense decided to remove the company from the CMC list under Section 1260H, based on the determination by the Deputy Secretary of Defense that it should comply with the court's ruling order approving the company's preliminary injunction motion.

This was not a voluntary correction. The wording of the announcement is clear: the removal was premised on "complying with the court's ruling," not on acknowledging that the previous designation was erroneous. Five months ago, on June 9, 2026, the company first announced it had been included on the list, and subsequently issued supplementary explanations twice more on June 12 and August 10, consistently characterizing the matter as "erroneously listed," and filed a preliminary injunction motion locally, pushing the dispute into judicial proceedings.

Jiang Han, a senior researcher at the Pangu Think Tank, stated that this judicially driven removal cannot directly erase the compliance concerns clients had accumulated previously. Internal reviews by overseas pharmaceutical companies will not immediately be fully relaxed; they simply no longer need to directly touch the red line of the list. Core compliance processes still need to be completed once more in full, and the substantive change is far smaller than a voluntary administrative revocation.

As of the close on November 12, WuXi AppTec Co.,Ltd. closed at 150.34 billion yuan, up 1.1%, with a total market value of approximately 456.3 billion yuan.

Formal removal from the list

On November 10, the core content of the major news disclosed by WuXi AppTec was less than 300 words, but it clearly presented the five-month tug-of-war process. The announcement stated that on November 9, 2026, the company noticed the Department of Defense's decision to remove it from the CMC list under Section 1260H, "with the Deputy Secretary of Defense determining that it should comply with the court's ruling order approving the company's preliminary injunction motion." At the end of the same announcement, the company reiterated that it will continue to serve clients, "empowering them to develop drugs that save and improve lives." Placed at the end of a regulatory announcement, this sentence is restrained in tone, clearly conveying the company's business positioning as a pharmaceutical R&D service provider.

The timeline can fully reconstruct this event. On June 9, 2026, the company first disclosed its inclusion on the CMC list, announcement number Lin 2026-021; on June 12, it issued a supplementary explanation, number Lin 2026-025; on August 10, it issued another announcement disclosing progress, number Lin 2026-033. In all three announcements, the company maintained that this inclusion constituted "erroneous listing." From June 9 to November 9, the entire event spanned five months, during which the company continued to disclose information on time and simultaneously advanced rights protection procedures within the local judicial system. Announcement numbers ran from 021 to 042, fully recording the entire regulatory battle.

To understand the significance of this removal, it is necessary to clarify the scope of impact of Section 1260H. This provision originates from the U.S. National Defense Authorization Act, under which the Department of Defense annually reviews and designates relevant companies to form the CMC list. Being placed on the list does not directly freeze a company's assets, nor does it immediately sever business dealings. The core impact comes from spillover compliance pressure. Related cooperation projects with the U.S. Department of Defense will be constrained, and more critically, compliance departments at multinational pharmaceutical companies will treat the list as a risk signal, lengthening the review cycle for new projects and adding special risk clauses to long-term framework agreements.

According to an analysis by Bai Wenxi, Vice Chairman of the China Enterprise Capital Alliance and Chief Economist for China, "First, the conclusion: this is a 'procedural delisting' rather than an 'overturning of the designation.' What is cured in the short term is client psychology, not order fundamentals; what still weighs on valuation is geopolitical uncertainty, while the industry cycle is actually the strongest positive variable right now. On client compliance reviews: psychological relief, but standards unchanged. Section 1260H itself does not trigger OFAC-style transaction bans; its impact is transmitted through client compliance processes. The August preliminary injunction already froze enforcement risk, so the direct incremental effect of delisting on short-term revenue and profit is limited. The key point is that the Department of Defense reserves the right to 'relist based on other reasons,' and the substantive dispute has not yet been finally adjudicated. The 'geopolitical risk' deduction in client assessments will not return to zero—especially for U.S. clients with federal contracts or NIH backgrounds, compliance questionnaires will still be completed, only with the additional favorable fact that 'the company is currently not on the list.'"

It can be seen that this delisting is a阶段性 result brought about by judicial proceedings and does not mean the relevant substantive dispute has been settled. After the list is removed, the market cannot simply interpret it as the complete elimination of operational constraints. Changes in client orders and business conversion still need continuous tracking and verification.

Business welcomes relaxation

The relaxation effect brought by the removal from the list is first reflected in client procurement and compliance review processes. When global large pharmaceutical companies screen R&D outsourcing suppliers, they need to verify technical capability, delivery quality, quality control systems, and compliance qualifications in sequence. The CMC list label was precisely the sticking point at the compliance stage. After the label is eliminated, clients' internal risk concerns are somewhat alleviated, but compliance review standards will not automatically be lowered.

Second is the improvement in cross-border funds, credit, guarantees, and other financial supporting links. During the period of being listed, many overseas financial institutions raised risk ratings, and the supporting conditions for cross-border financing and overseas capital expenditure tightened accordingly. After the removal, such frictions will gradually ease, but there is lag in updating internal risk control lists at financial institutions, so the release of benefits is a gradual process and difficult to realize all at once.

According to Bai Wenxi's analysis, regarding order回流, it is not a return but a shift from wait-and-see back to normal. During the five months of being listed, there was no large-scale order cancellation; clients engaged in wait-and-see and prudence, small and medium-sized biotechs added compliance buffer clauses, and MNCs diverted new molecules to South Korea and Europe, but short-term substitution is difficult. Therefore, what follows is the fading of the "chilling effect" on newly signed orders, rather than a return of existing business. In terms of pace, early-stage R-side inquiries respond fastest (1-2 quarters), while D/M-side split restoration is slower. The verification point is new order growth from Q4 to 2027H1—the already upward-revised backlog (76.74 billion yuan, +36.4%) relies on the rollover of existing pipelines, not on the credit of delisting.

Bai Wenxi further analyzed that from the perspective of geopolitical discount and industry cycle, geopolitics is the core and the cycle is the antidote, but the two are not on the same level. Geopolitics is the "source of discount," while the cycle is "profit realization." The 2026E forward PE is only about 17-19 times, compared with a comparable average of 33 times. This huge discount is almost entirely pricing geopolitical tail risk, and earnings upgrades can only catch up with part of it. The cycle is currently a tailwind: innovative drug financing is recovering, MNC R&D is rebounding, outsourcing rate has risen to 57%, and TIDES is +46.9%. The valuation ceiling is determined by geopolitics, while the performance floor is supported by the cycle; delisting only removes one brick, not the entire reason for a re-rating.

Jiang Han gave a judgment from the pace of order recovery: "Order return will not be explosive. Already delayed new orders will first restart on a small scale, and split long-term contracts will have to wait for clients' internal risk control processes to finish. It will probably take two to three quarters to gradually return to the previous order-taking pace, and it will not all come back at once." In his view, the underlying logic suppressing valuation also has another emphasis: "What suppresses valuation more fundamentally is still industry cycle pressure. The geopolitical discount is only a阶段性 emotional amplification. The slowdown in order growth caused by differentiation in innovative drug investment is the underlying reason the market truly cannot give a high premium."

The CXO industry is currently in a pattern of cyclical divergence. Global innovative drug R&D investment is uneven, with hot tracks such as GLP-1 and ADC having ample orders and stronger pricing power, while conventional R&D service tracks face intensifying competition and pressure on pricing. WuXi AppTec's core barrier comes from its integrated platform, relying on the "follow the molecule" model to intervene early in projects and accompany candidate drugs from early R&D and preclinical testing all the way to commercial production. The cost for clients to switch suppliers is high, which is also the core reason there was no large-scale loss of orders during the turmoil.

This dual-driver model of "follow the molecule + win the molecule" also continues to drive pipeline conversion. Third-quarter report data confirms business resilience: in the first three quarters of 2026, the small molecule D&M pipeline added 1,089 molecules; as of the end of September, the total pipeline was 3,863, including 103 commercial projects and 94 Phase III clinical projects, with a net increase of 23 commercial and Phase III projects in the period. Supported by the pipeline's continued advancement to later stages and supporting capacity and teams, small molecule D&M revenue in the first three quarters was 23.58 billion yuan, up 65.6% year on year.

To judge the substantive impact of this delisting, one cannot look only at short-term stock price fluctuations. The core is to track three indicators: the renewal and新增 scale of backlog orders, the proportion of overseas long-term framework agreements, and domestic and overseas capacity utilization. Only if the above indicators continue to improve over the next two to three quarters will it mean that the repair brought by this event has landed in fundamentals; if it remains only at the emotional level, then the market move is likely to be a case of good news being priced in.

After external compliance constraints loosen, the pace of corporate fundamental repair will ultimately depend on industry prosperity and clients' willingness to place orders.

The founder's path to breakthrough

In 2000, Li Ge, together with partners Zhao Ning, Liu Xiaozhong, Zhang Zhaohui, and others, established a laboratory in Wuxi and entered the then-blank domestic pharmaceutical R&D outsourcing track. Li Ge graduated from the Department of Chemistry at Peking University and later pursued a doctorate in organic chemistry at Columbia University in the United States. At that time, the domestic pharmaceutical industry was dominated by generic drugs, and splitting drug R&D into standardized, billable outsourcing services was an entirely new model at the time. This model also became the starting point for the development of China's CXO industry.

In 2007, WuXi AppTec listed on the New York Stock Exchange, making it one of the earlier Chinese pharmaceutical R&D service providers to go public in the United States. In 2015, the company completed privatization and delisting in a transaction of about US$3.3 billion, a landmark case of that year's China concept stock return wave. In May 2018, the company listed on the A-share market. From pre-disclosure to approval, it took a relatively short time, and the market called it "WuXi speed." The company's development path was built on a global layout, using overseas capital and overseas clients to hone its service system, then returning to the domestic capital market and gradually growing into a leading domestic CXO enterprise, deeply embedded in the global innovative drug R&D chain.

A global layout brings business scale while also making the company more vulnerable to shocks from changes in overseas regulatory policy. After being placed on the CMC list under Section 1260H in June 2026, the company's stock price continued to adjust, institutional disagreement increased, and the market continued to discuss the impact of geopolitical risk on the CXO growth logic.

Facing this regulatory designation, the company did not choose to wait passively but initiated judicial channels by filing a preliminary injunction motion, relying on legal avenues to protect its business rights. Bai Wenxi believes the replicability value of judicial rights protection is: the path can be copied, but the result is not guaranteed. WuXi AppTec proved that using the Administrative Procedure Act to challenge an "insufficient factual basis in the administrative record" is a viable countermeasure path. But its replicability value is limited: first, a preliminary injunction is not equal to a final victory, and Section 1260H is dynamically updated annually and can be repeatedly listed (AMEC was listed twice); second, the premise is that the factual basis of the designation itself is weak, and if a company does have sensitive ties, it is difficult to replicate; third, judicial cycles are long and costly, and small and medium-sized CXOs may not be able to afford it. It is a "defense sample," not an "immunity vaccine."

Bai Wenxi further analyzed that subsequent overseas regulatory risks must be noted, with the focus having shifted from Section 1260H to BCC and the capital side. There are three bigger gates: the BIOSECURE BCC list—OMB must publish the complete list by December 18, 2026, decoupled from Section 1260H. Even if not on 1260H, a company can still be listed as BCC through an independent procedure, enjoying a five-year transition period. This is a more substantive manufacturing-side decoupling risk than 1260H. In addition, watch for capital-side blockade: the COINS Act has opened a review channel, and if BINSA passes, it will bring China-U.S. licensing cooperation and joint ventures into mandatory review, threatening License-out and cross-border BD. FDA clinical data restrictions plus CFIUS: non-tariff barriers on the R&D side and normalized review of U.S. investment.

Bai Wenxi emphasized that this delisting is a "bad news exhausted" style emotional repair, not the endpoint of risk clearance. The U.S. strategy has shifted from "direct naming" to "mechanism binding," and creating uncertainty itself is a weapon. Just watch two numbers—Q4 new order growth (to verify client confidence) and OMB's BCC list (with December 18 as the boundary, determining whether the valuation discount can converge).

Jiang Han added a reminder that this rights protection model is not universally applicable. "The reference value of this rights protection case is limited. Not all overseas CXO companies have the ability to bear the long cost of judicial litigation. Different companies differ greatly in business structure and overseas legal resources, and this path cannot be directly copied." On subsequent risk prevention, he believes the market's focus also needs to broaden. "Going forward, the key is to guard against technology traceability reviews in export controls, as well as the牵连 of connected lists for other related entities. One cannot relax follow-up on subsequent regulatory developments just because of this delisting."

Over five months, WuXi AppTec achieved delisting through judicial procedures. This case provides a reference sample for overseas biopharmaceutical companies responding to unreasonable overseas administrative designations, but it does not mean similar companies can directly replicate it. For the management team, this victory only resolved the阶段性 problem of the 1260H list, and they will still need to continuously respond to diverse overseas regulatory tools. What do you think of this WuXi AppTec incident? Welcome to discuss in the comments section.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment